ROSEVILLE, Minn., Nov. 28, 2016 /PRNewswire/ -- Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it has engaged Ken F. Blount, Ph.D., as Head of External Research. At Rebiotix, Dr. Blount will be responsible for developing and executing external academic collaborations and strategic partnerships and conducting human feasibility studies for expanded indications involving Rebiotix' pioneering Microbiota Restoration Therapy (MRT).
Lee Jones, president and CEO of Rebiotix, commented, "We are delighted to have Dr. Blount join our Rebiotix team at such an exciting time of growth for our company. Dr. Blount is an experienced R&D entrepreneur who has initiated, directed, and grown collaborative research programs that delivered new drug candidates, high-profile discoveries, and funding in his past positions. This experience is bolstered by his extensive background in C. difficile infections, microbiology, antibiotics and oncology. He will be instrumental as we advance our MRT platform."
Dr. Blount most recently was an Associate Research Scientist/Scholar, Translational Research Coordinator at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, where he established five new clinical-scientist translational research collaborations in oncology. In addition, Dr. Blount was the co-founder and Director of Biology at BioRelix, a start-up biotechnology company with a platform of novel C. difficile antibiotics. Dr. Blount received his Ph.D. in Chemistry and Biochemistry at the University of Colorado, Boulder and conducted his post-doctoral fellowship at the National Institute of Health at the University of California, San Diego, Department of Chemistry.
About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having successfully completed a Phase 2b randomized, double-blind, placebo-controlled trial as a possible prevention of recurrent Clostridium difficile (C. diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to treat recurrent C. diff. infection. Rebiotix's development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Tiberend Strategic Advisors, Inc.
SOURCE Rebiotix Inc.